Omeros Corporation (NASDAQ:OMER – Get Free Report) CAO David Borges sold 906 shares of the stock in a transaction that occurred on Monday, August 24th. The shares were sold at an average price of $19.10, for a total value of $17,304.60. Following the completion of the sale, the chief accounting officer directly owned 5,906 shares of the company’s stock, valued at approximately $112,804.60. The trade was a 13.30% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Omeros Stock Performance
OMER traded down $0.04 during trading on Tuesday, reaching $19.28. 1,314,611 shares of the stock were exchanged, compared to its average volume of 1,716,966. The stock’s 50 day moving average price is $11.93 and its two-hundred day moving average price is $11.81. Omeros Corporation has a twelve month low of $3.94 and a twelve month high of $19.65. The stock has a market cap of $1.40 billion, a P/E ratio of 15.06 and a beta of 2.54.
Omeros (NASDAQ:OMER – Get Free Report) last announced its quarterly earnings data on Thursday, August 13th. The biopharmaceutical company reported $0.02 EPS for the quarter, beating analysts’ consensus estimates of ($0.27) by $0.29. The firm had revenue of $28.53 million during the quarter, compared to the consensus estimate of $12.69 million. Equities research analysts predict that Omeros Corporation will post -0.37 earnings per share for the current fiscal year.
Institutional Investors Weigh In On Omeros
Analyst Upgrades and Downgrades
A number of equities research analysts recently weighed in on the company. Zacks Research cut Omeros from a “strong-buy” rating to a “hold” rating in a research note on Monday, July 13th. HC Wainwright reissued a “buy” rating on shares of Omeros in a research report on Monday, July 27th. Weiss Ratings upgraded shares of Omeros from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Wednesday, August 5th. Finally, Wall Street Zen upgraded shares of Omeros from a “hold” rating to a “buy” rating in a research note on Saturday, August 15th. One equities research analyst has rated the stock with a Strong Buy rating, two have given a Buy rating and three have assigned a Hold rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $38.00.
Get Our Latest Stock Analysis on OMER
Omeros Company Profile
Omeros Corporation is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of small-molecule and protein therapeutics. The company’s research programs target inflammation, complement-mediated diseases and disorders of the central nervous system. Omeros’s portfolio encompasses both internally discovered molecules and biologics, reflecting its commitment to advancing treatments for conditions with high unmet medical need.
Omeros’s first FDA-approved product, Omidria® (phenylephrine and ketorolac intraocular solution), is indicated to maintain pupil size by preventing intraoperative miosis and reducing postoperative pain in patients undergoing cataract surgery.
Featured Articles
- Five stocks we like better than Omeros
- Pathward’s Credit Scare Tests Its Comeback Story
- Wiring the AI Boom: Rumble’s $13.7B Pivot
- StoneX: Too Far Too Fast?
- DICK’s Sporting Goods Faces Pain Now for a Bigger Prize
Receive News & Ratings for Omeros Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omeros and related companies with MarketBeat.com's FREE daily email newsletter.
